

Efficient Patient Recruitment for Innovative Clinical Trials of Existing Drugs to other Indications

www.ponte-project.eu


http://cordis.europa.eu/fp7/ict/ http://ec.europa.eu/information\_society

## **@Health**



## PONTE: A Context-Aware Approach for Automated Clinical Trial Protocol Design

George Tsatsaronis, Michael Schroeder





Konstantinos Mourtzoukos, Vassiliki Andronikou, Tassos Tagaris, Theodora Varvarigou, Dimitris Koutsouris NTUA, Greece



**Iraklis Varlamis** HUA, Greece



Nikolaos Matskanis CETIC, Belgium



(Presenter)





## Layout


- Introduction to the PONTE EU project
- A Context-Aware Architecture for CTP design
  - Architecture
  - Context-Aware Parameters
- Decision Support
- Intelligent Semantic Search
- Real-World Scenario: An example of usage

# Introduction to the PONTE EU Project

- Average Drug Development cost: €500-700 million per drug candidate timeline: more than 10 years.
- Tremendous reduction in new active ingredients reaching the market yearly:
  - ~ 60/year (late 1980s), 52 (1991), 31 (2001), 20-25 (currently)
- Clinical trials :
  - ~ 1/3 of the costs of drug development <u>half of which</u> depends on duration
  - Low recruitment rates Long recruitment periods
  - Subjects recruited represent only partially the target patient population
  - Mortality rates in clinical study findings vs real life
  - 1 out of 5000 new drug candidates reach the market
- Drug repositioning trend and Complex tests of hypothesis: testing new treatments of existing drugs on patients suffering from another disorder
- Humans' high variability in response to a drug treatment requires *large-scale clinical trial* conduction for ensuring that the investigational treatment is safe and effective



# Clinical Trials: Currently





the 7th Framework Programme

#### The PONTE Solution

- Development of a research question into a Clinical Trial
- Clinical Trial design management
  - Effective decision support
  - Efficient navigation capabilities
  - Adaptive Study Design
  - Intelligent semantic search in distributed drug, disease and clinical trials data sources
- Secure and Privacy-preserving interlinking with EHRs






## The PONTE platform

- Test of Hypothesis Evaluation
- Clinical Trial Protocol Authoring Tool
- Intelligent search of data sources through the platform (PubMed, ClinicalTrials.org, drug/disease data)
- Guidance in the determination of study parameters through available predefined queries and efficient decision support services
- Adaptive clinical trial design by evaluating the level of confidence for each protocol parameter
- Efficient determination of target population focusing on patient safety, clinical trial efficacy and cost






#### A Context-Aware Architecture for CTP Design








#### **Context-Aware Parameters**








## The Power of Biological Networks and Linked-Data








## Context-Aware Decision Support







#### Intelligent Semantic Search







#### Real-World Scenario: Example of Usage

- Drug: Amiodarone
- Disease: acute myocardial infarction
- Targets: May be retrieved automatically from DS and GoPonte
- Automatically generated queries:

#### Predefined Queries


Epidemiology of the Acute myocardial infarction
Acute myocardial infarction pathophysiology
Standard Treatments for Acute myocardial infarction
Comorbitities of the Acute myocardial infarction

```
amiodarone interactions with other drugs
amiodarone interactions with food
amiodarone AND potassium voltage-gated channel, subfamily H (eag-related), member 2(KCNH2)
amiodarone AND adrenergic, beta-1-, receptor(ADRB1)
amiodarone AND adrenergic, alpha-1A-, receptor(ADRA1A)
amiodarone AND adrenergic, alpha-1B-, receptor(ADRA1B)
amiodarone AND adrenergic, alpha-1D-, receptor(ADRA1D)
amiodarone AND cytochrome P450, family 2, subfamily D, polypeptide 6(CYP2D6)
amiodarone AND cytochrome P450, family 2, subfamily C, polypeptide 9(CYP2C9)
amiodarone AND cytochrome P450, family 1, subfamily A, polypeptide 2(CYP1A2)
amiodarone AND cytochrome P450, family 3, subfamily A, polypeptide 4(CYP3A4)
amiodarone AND Resting heart rate, 607276
amiodarone AND Long QT syndrome-2
```





#### Context-Aware and Automatically Guided Semantic Search







## Thank You

More information:

www.ponte-project.eu

# 2<sup>nd</sup> iteration:: Dissemination

System	Document Type	Ontologies	Text Mining	Results type
Google	Web pages/documents	-	synonym expansion	snippets
<b>g</b> pubmed°	Abstracts, xml	Gene Ontology, MeSH	entities and concepts recognition, annotation (classification)	Snippets, induced ontology, abstracts
Ponte (beta)	Abstracts	Gene Ontology, MeSH , PONTE	entities and concepts recognition, annotation (classification)	Snippets, induced ontology
Pente	Abstracts, semistructured documents, web pages	PONTE	entities and concepts recognition, annotation (classification)	Snippets, induced ontology, abstracts/documents




Efficient Patient Recruitment for Innovative Clinical Trials of Existing Drugs to other Indications

www.ponte-project.eu



## Discussion of Functionality: Linked Data



Single search results with search terms highlighted in green further identified entities in bold, hyperlink to full text in grey (bottom), and export button (upper left).

Starting the expansion of the search to the Linked Data for the term "myocardial infarction" by clicking on the corresponding entry.



[2010-12-15]

auses substantial morbidity and

B. Recently, attention has shifted

Linked Data